Centromere 17 Copy Number Gain Reflects Chromosomal Instability in Breast Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2019 Dec 1

PMID 31784614

Citations 12

Authors

Kyoungyul Lee

Hyun Jeong Kim

Min Hye Jang

Sejoon Lee

Soomin Ahn

So Yeon Park

Affiliations

Soon will be listed here.

Abstract

Chromosomal instability (CIN) is known to be associated with prognosis and treatment response in breast cancer. This study was conducted to determine whether copy number gain of centromere 17 (CEP17) reflects CIN, and to evaluate the prognostic and predictive value of CIN in breast cancer. CIN status was determined by summing copy number gains of four centromeric probes (CEP1, CEP8, CEP11, and CEP16) based on fluorescence in situ hybridization and CIN scores were calculated using next generation sequencing data. High CIN was associated with adverse clinicopatholgical parameters of breast cancer. Among them, positive HER2 status, high Ki-67 index and CEP17 copy number gain were found to be independent predictors of high CIN. High CIN was associated with poor clinical outcome of the patients in the whole group, as well as in luminal/HER2-negative and HER2-positive subtypes. CEP17 copy number was significantly higher in the high-CIN-score group than in the low-CIN-score group. A positive linear correlation between the mean CEP17 copy number and the CIN score was found. In conclusion, CEP17 copy number was confirmed as a useful predictor for CIN in breast cancer, and high CIN was revealed as an indicator of poor prognosis in breast cancer.

Citing Articles

A new insight into the impact of copy number variations on cell cycle deregulation of luminal-type breast cancer.

Mahdi Khamaneh A, Jafari-Gharabaghlou D, Ansarin K, Pazooki P, Akbarpour Z, Naghili B Oncol Rev. 2025; 19:1516409.

PMID: 40017494 PMC: 11861078. DOI: 10.3389/or.2025.1516409.

High chromosomal instability is associated with higher 10-year risks of recurrence for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: clinical evidence from a large-scale, multiple-site,....

Liao Y, Fu J, Lu X, Qian Z, Yu Y, Zhu L J Pathol Clin Res. 2024; 10(6):e70011.

PMID: 39545625 PMC: 11565440. DOI: 10.1002/2056-4538.70011.

Patterns of Chromosomal Instability and Clonal Heterogeneity in Luminal B Breast Cancer: A Pilot Study.

Camargo-Herrera V, Castellanos G, Rangel N, Jimenez-Tobon G, Martinez-Aguero M, Rondon-Lagos M Int J Mol Sci. 2024; 25(8).

PMID: 38674062 PMC: 11049937. DOI: 10.3390/ijms25084478.

Clinical application of the HM-1000 image processing for HER2 fluorescence in situ hybridization signal quantification in breast cancer.

Peg V, Moline T, Roig M, Saruta Y, Cajal S Diagn Pathol. 2024; 19(1):32.

PMID: 38360676 PMC: 10868098. DOI: 10.1186/s13000-024-01455-8.

Osteosarcoma Multi-Omics Landscape and Subtypes.

Tang S, Roberts R, Cheng L, Li L Cancers (Basel). 2023; 15(20).

PMID: 37894336 PMC: 10605601. DOI: 10.3390/cancers15204970.

References

Bartlett J, Munro A, Dunn J, McConkey C, Jordan S, Twelves C . Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 2010; 11(3):266-74. DOI: 10.1016/S1470-2045(10)70006-1. View

Krishnamurti U, Hammers J, Atem F, Storto P, Silverman J . Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Mod Pathol. 2009; 22(8):1044-8. DOI: 10.1038/modpathol.2009.61. View

Tibau A, Lopez-Vilaro L, Perez-Olabarria M, Vazquez T, Pons C, Gich I . Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer. Neoplasia. 2014; 16(10):861-7. PMC: 4212250. DOI: 10.1016/j.neo.2014.08.012. View

Spears M, Lyttle N, DCosta A, Chen B, Yao C, Boutros P . A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial. Oncotarget. 2016; 7(31):49099-49106. PMC: 5226493. DOI: 10.18632/oncotarget.8542. View

Endesfelder D, McGranahan N, Birkbak N, Szallasi Z, Kschischo M, Graham T . A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables. Oncotarget. 2011; 2(7):529-37. PMC: 3248181. DOI: 10.18632/oncotarget.298. View

Hanna W, Ruschoff J, Bilous M, Coudry R, Dowsett M, Osamura R . HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol. 2013; 27(1):4-18. DOI: 10.1038/modpathol.2013.103. View

Thompson P, Brewster A, Kim-Anh D, Baladandayuthapani V, Broom B, Edgerton M . Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. PLoS One. 2011; 6(8):e23543. PMC: 3155554. DOI: 10.1371/journal.pone.0023543. View

Vargas-Rondon N, Villegas V, Rondon-Lagos M . The Role of Chromosomal Instability in Cancer and Therapeutic Responses. Cancers (Basel). 2017; 10(1). PMC: 5789354. DOI: 10.3390/cancers10010004. View

Downs-Kelly E, Yoder B, Stoler M, Tubbs R, Skacel M, Grogan T . The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol. 2005; 29(9):1221-7. DOI: 10.1097/01.pas.0000165528.78945.95. View

10.

Lee K, Jang M, Chung Y, Lee Y, Kang E, Kim S . Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype. Hum Pathol. 2016; 61:111-120. DOI: 10.1016/j.humpath.2016.12.004. View

11.

Thompson S, Bakhoum S, Compton D . Mechanisms of chromosomal instability. Curr Biol. 2010; 20(6):R285-95. PMC: 3781365. DOI: 10.1016/j.cub.2010.01.034. View

12.

Smid M, Hoes M, Sieuwerts A, Sleijfer S, Zhang Y, Wang Y . Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. Breast Cancer Res Treat. 2010; 128(1):23-30. DOI: 10.1007/s10549-010-1026-5. View

13.

Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31(31):3997-4013. DOI: 10.1200/JCO.2013.50.9984. View

14.

Bakhoum S, Compton D . Chromosomal instability and cancer: a complex relationship with therapeutic potential. J Clin Invest. 2012; 122(4):1138-43. PMC: 3314464. DOI: 10.1172/JCI59954. View

15.

Kim A, Shin H, Bae Y, Kim M, Kang S, Lee S . Multiplication of Chromosome 17 Centromere Is Associated with Prognosis in Patients with Invasive Breast Cancers Exhibiting Normal HER2 and TOP2A Status. J Breast Cancer. 2012; 15(1):24-33. PMC: 3318171. DOI: 10.4048/jbc.2012.15.1.24. View

16.

Vanden Bempt I, Van Loo P, Drijkoningen M, Neven P, Smeets A, Christiaens M . Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol. 2008; 26(30):4869-74. DOI: 10.1200/JCO.2007.13.4296. View

17.

Vincent-Salomon A, Benhamo V, Gravier E, Rigaill G, Gruel N, Robin S . Genomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomas. PLoS One. 2013; 8(10):e76496. PMC: 3797106. DOI: 10.1371/journal.pone.0076496. View

18.

. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70. PMC: 3465532. DOI: 10.1038/nature11412. View

19.

Munro A, Twelves C, Thomas J, Cameron D, Bartlett J . Chromosome instability and benefit from adjuvant anthracyclines in breast cancer. Br J Cancer. 2012; 107(1):71-4. PMC: 3389422. DOI: 10.1038/bjc.2012.232. View

20.

Michor F, Iwasa Y, Vogelstein B, Lengauer C, Nowak M . Can chromosomal instability initiate tumorigenesis?. Semin Cancer Biol. 2004; 15(1):43-9. DOI: 10.1016/j.semcancer.2004.09.007. View